RxDoctor Payments Data

Jessica Rosario

General Practice · Santurce, PRNPI 1013035013

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $29,750 of the $40,830 with a category attached, or 72.9%. Viiv Healthcare Company accounts for 77.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $10,392 and has fallen 74.1% since, to $2,695 in 2025. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,830in general payments, 2019–2025

Across 244 payments — averaging $167.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$31K
  • Merck$4K
  • Gilead$2K
  • Theratechnologies Inc.$2K
  • Johnson & Johnson$1K
  • AbbVie$125
  • plus $225 from 5 others

What the payments were for

  • Consulting fees$29,75073%
  • Speaking & faculty fees$1,1253%
  • Travel & lodging$4881%
  • Food & beverage$9,43723%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,830 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala209$907,789
DovatoDolutegravir Sodium/Lamivudine116$352,183
TriumeqAbacavir/Dolutegravir/Lamivudi76$334,202
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf65$323,341
JulucaDolutegravir/Rilpivirine84$308,982
TivicayDolutegravir Sodium103$248,821
DescovyEmtricitabine/Tenofov Alafenam101$226,665
PrezcobixDarunavir/Cobicistat70$181,703
Isentress HdRaltegravir Potassium79$156,973
OdefseyEmtricitab/Rilpiviri/Tenof Ala42$152,449
PifeltroDoravirine49$89,391
GenvoyaElviteg/Cob/Emtri/Tenof Alafen18$71,891
PrezistaDarunavir22$46,647
IsentressRaltegravir Potassium11$21,792
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Triumeq, Juluca, Tivicay$31,474$1,244,188379 claims
GileadBiktarvy, Descovy, Genvoya$2,163$1,206,345328 claims
Janssen Products, LPSymtuza$30$323,34165 claims
MerckIsentress Hd, Pifeltro, Isentress, Januvia$3,635$274,509150 claims
Johnson & JohnsonPrezcobix$1,467$181,70370 claims
GSKTrelegy Ellipta$25$13,32520 claims
AbbVieSynthroid$125$1,24723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Santurce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →